Journal of Endocrinological Investigation最新文献

{"title":"Shepherd with goiter in the late-Renaissance Nativity scene of the Canonica di San Salvatore in Barzanò.","authors":"Michele Augusto Riva","doi":"10.1007/s40618-025-02539-y","DOIUrl":"10.1007/s40618-025-02539-y","url":null,"abstract":"","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"1289-1291"},"PeriodicalIF":5.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current drawbacks and future perspectives in the diagnosis and treatment of male factor infertility, with a focus on FSH treatment: an expert opinion.","authors":"D Santi, G Corona, A Salonia, A Ferlin","doi":"10.1007/s40618-024-02524-x","DOIUrl":"10.1007/s40618-024-02524-x","url":null,"abstract":"<p><strong>Purpose: </strong>Infertility is defined as the inability to conceive after 1 year of unprotected intercourse, affecting approximately 15-20% of couples in Western countries. It is a shared problem within the couple; when the main issue lies with one of the partners, it is preferable to refer to \"male factor\" or \"female factor\" infertility rather than simply male or female infertility. Despite male factor infertility accounting for half of all couple infertility cases, the clinical approach to the male partner is not uniformly standardized across international guidelines.</p><p><strong>Methods: </strong>To provide an expert overview, we have comprehensively reviewed and critically analyzed the most up-to-date literature on this sensitive topic, leading to the development of a proposal for tailored assessment of the diagnostic-therapeutic pathway and preventive strategies. The diagnostic approach also considers that infertile men are objectively less healthy than their fertile counterparts of the same age and ethnicity.</p><p><strong>Results: </strong>This article discusses the diagnostic flow, the classification of male factor infertility, the definition of idiopathic infertility, the involvement of general health, and treatment recommendations, emphasizing follicle-stimulating hormone treatment in selected groups of patients.</p><p><strong>Conclusion: </strong>We provide expert opinion on current drawbacks and future perspectives in this field, with practical advice for the clinical practice of general practitioners and expert in reproductive medicine.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"1085-1100"},"PeriodicalIF":5.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth hormone replacement therapy enhances humoral response to COVID-19 mRNA vaccination in patients with adult-onset growth hormone deficiency.","authors":"Davide Masi, Maria Elena Spoltore, Mariaignazia Curreli, Denise Costa, Elena Gangitano, Stefania Mariani, Antonio Angeloni, Lucio Gnessi, Emanuela Anastasi, Carla Lubrano","doi":"10.1007/s40618-024-02528-7","DOIUrl":"10.1007/s40618-024-02528-7","url":null,"abstract":"<p><strong>Purpose: </strong>Given the established link between GH/insulin-like growth factor 1 (IGF-1) deficiency and severe COVID-19 outcomes, this research seeks to determine whether GH therapy can enhance vaccine efficacy in patients with adult-onset growth hormone deficiency (aGHD).</p><p><strong>Methods: </strong>We conducted an observational retrospective study involving two groups: a cohort of 10 patients (8 females, 2 males) with obesity and aGHD who initiated recombinant GH replacement therapy at a standard dose of 0.1 mg/day six months to one year before their first vaccine dose, and a matched control group of 7 patients (5 females, 2 males) with aGHD who had not started GH treatment. Both groups were matched for age, gender, and body mass index (BMI) to ensure comparability. Blood samples were collected 3 to 6 months after the third booster dose of the COVID-19 vaccine (BNT162b2, Pfizer-BioNTech) and analyzed for anti-SARS-CoV-2 antibodies using a commercially available assay.</p><p><strong>Results: </strong>The GH-treated group exhibited a significantly greater humoral response compared to the untreated group, with a mean antibody titer of 19,122.1 ± 7,736.84 U/mL versus 9,539.14 ± 5,408.90 U/mL in the control group (p = 0.01). Multivariate regression analysis revealed that GH replacement therapy was the only statistically significant predictor of vaccine response, while factors such as male sex, age, and visceral adipose tissue showed negative correlations that did not reach significance.</p><p><strong>Conclusion: </strong>Our findings suggest that GH replacement therapy may enhance the immune response to COVID-19 vaccination in patients with aGHD, potentially improving their overall metabolic health and immune function.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"1283-1288"},"PeriodicalIF":5.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual health in adult women with complete androgen insensitivity syndrome: a single centre cross-sectional study.","authors":"Alessandra Mangone, Eriselda Profka, Giulia Rodari, Claudia Giavoli, Giovanna Mantovani","doi":"10.1007/s40618-025-02592-7","DOIUrl":"https://doi.org/10.1007/s40618-025-02592-7","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to assess sexual health and body uneasiness in patients with complete androgen insensitivity syndrome (CAIS) using validated questionnaires, since literature is limited and heterogeneous.</p><p><strong>Methods: </strong>Single-center, cross-sectional study on 34 adults with 46, XY karyotype and confirmed androgen receptor mutation (age = 34 ± 8.6 years), 29 gonadectomized and 5 with gonads in situ. All gonadectomized patients but 3 were receiving hormonal replacement therapy (HRT): 14 with transdermal oestradiol, 10 with oral oestradiol, 2 with testosterone. We measured hormonal levels and adherence to HRT, and we administered Female Sexual Function Index (FSFI), Female Sexual Distress Scale-Revised (FSDS-R) and Body Uneasiness Test (BUT) questionnaires.</p><p><strong>Results: </strong>We registered sexual dysfunction with FSFI score < 26.55 and FSDS-R score > 11 respectively in 77% and 52.9% of the cohort; body uneasiness (BUT-Global Severity Index > 1.2) was also present in 50%. In patients with gonads in situ, body uneasiness and sexual distress were common, with 4/5 pathological scores at FSFI and BUT, and 2/5 at FSDS-R. In gonadectomized patients, no significant differences among type of HRT and questionnaires' results were registered. Despite receiving HRT and referring optimal compliance, most (69%) patients still had oestradiol concentration < 50 pg/ml, with no significant correlation with sexual function. 10/34 patients (29%) had vaginal hypoplasia and 9 underwent vaginal dilation treatment, with no correlation with sexual scores.</p><p><strong>Conclusions: </strong>Sexual dysfunction and body uneasiness are worryingly common in CAIS. Preservation of gonads and HRT do not guarantee adequate sexual function nor optimal hormone levels. Psychological and sexual aspects must be considered in the management and therapeutic choices for these patients, as they highly impact quality of life.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis.","authors":"Shuzhen Lin, Xiaodan Ou, Liangchun Cai, Wenxin Huang, Junping Wen","doi":"10.1007/s40618-025-02595-4","DOIUrl":"https://doi.org/10.1007/s40618-025-02595-4","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to investigate efficacy and safety of TCZ in TED.</p><p><strong>Methods: </strong>Performing a meta-analysis of included studies. PubMed, Web of Science, Embase, Cochrane Library, and Clinicatrials.gov databases were retrieved to identify all related published literatures as of May 2024. When I² > 50%, the random effect model was used; otherwise, the fixed model was used.</p><p><strong>Results: </strong>This meta-analysis included 413 patients with TED. Therapeutic effect of TCZ was evaluated by various metrics, including clinical activity score (CAS), response rate, inactivation rate, proptosis, visual acuity (VA), TRAB/TSI levels, diplopia, eye motility, intraocular pressure (IOP), and relapse rate. The final analysis revealed that TCZ significantly reduced CAS (-4.47, 95%CI [-5.14, -3.79]), with high response rate (0.93, 95%CI [0.88, 0.97]) and inactivation rate (0.90, 95%CI [0.83, 0.96]). Significant improvements were also observed in proptosis (2.05 mm reduction, 95%CI [-2.42, -1.67]) and diplopia (0.56 improvement rate, 95% CI [0.40, 0.72]). Regarding safety, the pooled incidence of adverse events (AEs) was 0.31(95%CI [0.15, 0.48]). Hyperlipidemia was the most prevalent AE, followed by neutropenia and infection. Furthermore, subgroup analysis demonstrated TCZ's superior performance in terms of inactivation rate, antibody decline rate, relapse rate, and safety.</p><p><strong>Conclusions: </strong>According to the best available evidence, TCZ appears to be an acceptable alternative for moderate to severe TED patients due to its significant efficacy, well-tolerability, and low relapse rate. Larger sample size and controlled studies are warranted to promote the position of TCZ in TED treatment.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes mellitus secondary to endocrine diseases: a position statement of the working group of the club of the Italian society of endocrinology (SIE)-Nutrition hormones and metabolism.","authors":"Luigi Barrea, Massimiliano Caprio, Sebastio Perrini, Elisabetta Camajani, Andrea Crafa, Elena Gangitano, Stefania Gorini, Laura Sciacca, Ludovica Verde, Manuela Albertelli, Diego Ferone, Francesco Giorgino, Annamaria Colao, Gianluca Aimaretti, Giovanna Muscogiuri","doi":"10.1007/s40618-025-02589-2","DOIUrl":"https://doi.org/10.1007/s40618-025-02589-2","url":null,"abstract":"<p><strong>Purpose: </strong>This position statement addressed the limited scientific literature on the management of diabetes mellitus secondary to endocrinopathies, despite its frequent occurrence in hormonal diseases such as acromegaly, Cushing's syndrome, primary hyperaldosteronism, pheochromocytoma, hyperthyroidism, and neuroendocrine tumors. The aim was to review the pathophysiological mechanisms, clinical features, and management strategies, focusing on nutritional and pharmacological approaches.</p><p><strong>Methods: </strong>A comprehensive review of existing literature was conducted regarding studies on diabetes secondary to endocrinopathies and the effects of treatments for these conditions, such as somatostatin analogues and pancreatic surgery. Particular emphasis was placed on understanding glucose metabolism derangements and the interplay between endocrine excess and therapeutic interventions.</p><p><strong>Results: </strong>Secondary diabetes arises not only from hormone excess but also as a consequence of treatments for endocrine disorders. For instance, somatostatin analogues, while effective in resolving hormone hypersecretion, impair glucose metabolism by inhibiting pancreatic insulin secretion. Similarly, pancreatic surgery for neuroendocrine tumors often exacerbates glycemic disturbances. The management of secondary diabetes requires a multidisciplinary approach that includes treating the underlying endocrine disorder, tailoring antidiabetic therapy, and optimizing nutritional strategies to mitigate metabolic disruptions.</p><p><strong>Conclusion: </strong>Diabetes secondary to endocrinopathies presents unique challenges due to its complex etiology and the metabolic effects of treatments. This position statement underscores the importance of an integrated management approach, offering guidance for clinicians in addressing this multifaceted condition. Further research is needed to develop evidence-based guidelines for optimal care.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric and adolescent von Hippel-Lindau disease: tumor profiles, genotype-phenotype correlation and comparison with adults.","authors":"Anima Sharma, Ketki Ambulkar, Manjiri Karlekar, Saba Samad Memon, Virendra Patil, Nitish Agarwal, Vijaya Sarathi, Anurag Lila, Sameer Rege, Gaurav Malhotra, Hemangini Thakkar, Rohit Barnabas, Nalini Shah, Tushar Bandgar","doi":"10.1007/s40618-025-02571-y","DOIUrl":"https://doi.org/10.1007/s40618-025-02571-y","url":null,"abstract":"<p><strong>Purpose: </strong>Data on pediatric/adolescent von Hippel-Lindau (VHL) disease is sparse, and surveillance/management recommendations rely on expert opinions/extrapolations from adults. We aimed to characterize the childhood/adolescent VHL disease phenotype, compare it with adults, and identify genotype-phenotype correlations.</p><p><strong>Methods: </strong>Retrospective review of children/adolescents (≤ 19 years) and adults with VHL disease from a single endocrine center (2000-2024). Only neoplasms diagnosed until age 19 years were included in the childhood/adolescent group and compared with the last follow-up of adults.</p><p><strong>Results: </strong>Twenty-six children/adolescents (median age:15.5 years) were identified. By age 19 years, 81% had pheochromocytoma/paraganglioma (PPGL, of which 10% head-neck), 42% central nervous system hemangioblastoma (CNS-HB), 31% each retinal hemangioblastoma (RHB) and pancreatic neuroendocrine tumor (PNET), and none endolymphatic sac tumor/renal cell carcinoma. At diagnosis, all PPGLs were symptomatic (median size 4.5 cm). CNS-HBs showed female preponderance, with high disease burden (60% symptomatic, 50% synchronous) and surgical requirement by 19 years of age. 2/8 pediatric patients needed surgery for symptomatic PNET before recommended surveillance initiation age (15 years). Two children/adolescents developed polycythemia during follow-up. Compared to adults (n = 39), pediatric/adolescent PPGL patients had significantly higher plasma free-normetanephrine/bilateral/extra-adrenal disease and 8.3-fold higher operative-site recurrence. Neoplasm frequency and other characteristics by 19 years resembled adults. Childhood/adolescent PPGLs occurred predominantly (16/17), and PNETs exclusively with missense variants. Codon 167 missense variants were associated with synchronous bilateral pheochromocytomas.</p><p><strong>Conclusion: </strong>In the largest Asian study describing children/adolescents with VHL disease, we report severe pediatric/adolescent phenotype comparable to adults, need for childhood/adolescent HNPGL, and earlier PNET surveillance, particularly with missense variants.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exposure profiles to Benzophenones and their impacts on thyroid hormones in pregnant women.","authors":"Khelfi Abderrezak, Askoufes Houyam, Alsayed Ahmad Dana, Afri Yamina, Talhi Randa, Henkel Ralf, Azzouz Mohamed","doi":"10.1007/s40618-025-02570-z","DOIUrl":"https://doi.org/10.1007/s40618-025-02570-z","url":null,"abstract":"<p><strong>Purpose: </strong>Benzophenones are ubiquitous compounds widely used in various industrial and consumer products including sunscreens, plastics, and personal care items. Their presence as emerging pollutants has raised concerns due to their potential adverse health effects, particularly as endocrine disrupting chemicals (EDCs). The aim of this study was to identify exposure profiles to Benzophenones in pregnant women living in Algiers and to explore associations between urinary levels of these compounds and disruptions of thyroid hormones levels during pregnancy.</p><p><strong>Methods: </strong>This study was carried out on 384 pregnant women. After gathering necessary information using a questionnaire, blood and urine samples were collected. Thyroid hormones (TSH, FT3, and FT4) were measured by electrochemiluminescence while Benzophenones (BP-1, BP-2, and BP-3) were detected by LC-MS/MS.</p><p><strong>Results: </strong>BP-1, BP-2, and BP-3 were detected in 91.9%, 56.5%, and 88.3% of the analyzed samples, respectively. Mean concentrations were 2.250, 0.178, and 2.067 µg/g creatinine for BP-1, BP-2, and BP-3, respectively. Significant negative associations were found between plasma levels of FT3 and urinary concentrations of both BP-1 (β = -0.101) and BP-3 (β = -0.110). Moreover, significant positive associations were recorded between urinary concentrations of both BP-1 and BP-3 and the application of makeup.</p><p><strong>Conclusion: </strong>In conclusion, exposure of pregnant women to Benzophenones may affect levels of thyroid hormones resulting in possible adverse health effects on the mother and the development of the child. Therefore, preventive measures limiting exposure to these EDCs are recommended.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trabecular bone score as a possible new surgical recommendation in patients with asymptomatic primary hyperparathyroidism.","authors":"Nicolò Bisceglia, Matteo Malagrinò, Cristiana Cantone, Sara Capra, Anna Piazza, Giulia Vandi, Guido Zavatta","doi":"10.1007/s40618-025-02590-9","DOIUrl":"https://doi.org/10.1007/s40618-025-02590-9","url":null,"abstract":"<p><strong>Purpose: </strong>TBS usefulness in primary hyperparathyroidism (PHPT) management is uncertain. The primary aim was to evaluate the significance of performing Trabecular Bone Score (TBS) in addition to classical PHPT surgical recommendations. The explorative objective was to characterize bone quality in a cohort of patients with asymptomatic PHPT.</p><p><strong>Methods: </strong>From 1/1/2021 to 5/31/2024, of 265 consecutively evaluated PHPT patients, 125 met inclusion and exclusion criteria. Patients underwent complete biochemical evaluation in the same laboratory, Dual Energy X-ray Absorptiometry (DXA) at three sites, TBS with the same densitometer, and renal ultrasound. We retrospectively applied to each patient all the criteria to recommend parathyroidectomy as per the Fifth International Workshop, adding also TBS ≤ 1.2.</p><p><strong>Results: </strong>Almost one-third of patients presented degraded TBS (≤ 1.2), 36.0% partially degraded TBS, and 31.2% preserved TBS (≥ 1.35). Mean TBS was partially degraded (1.286 ± 0.134). Osteoporotic patients had lower TBS than osteopenic patients (1.207 ± 0.101 vs. 1.27 9 ± 0.110; p <.001). Patients with degraded TBS had a greater number of fragility fractures than those with TBS > 1.2 (34.2% vs. 8.3%; p <.001). In the group of osteopenic patients (34.4%), 10/43 (23.3%) showed degraded TBS. 13 patients (10.4%) did not meet any surgical criteria, and of these, 3/13 (23.1%) had degraded TBS and were osteopenic.</p><p><strong>Conclusion: </strong>More than one-fifth of patients who did not meet the current surgical recommendations presented degraded TBS and osteopenia. The combination of degraded TBS and osteopenia as a possible new surgical recommendation could increase the number of patients who might benefit from curative parathyroidectomy, with potential reduction of fracture risk.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of diabetic ketoacidosis, islet cell function, and age of onset on pancreas size, morphology, and exocrine function in children with type 1 diabetes: an abdominal MRI study.","authors":"Zheng Cai, Shaoqing Chen, Mingxin Chen, Shuang Meng, Yixuan Hu, Mei Huang, Jiawen Song, Xiaoyan Huang, Zhihan Yan, Kun Liu","doi":"10.1007/s40618-025-02591-8","DOIUrl":"https://doi.org/10.1007/s40618-025-02591-8","url":null,"abstract":"<p><strong>Objective: </strong>To investigate pancreatic MRI parameters changes in children with T1D and to assess the effects of DKA, islet cell function, and onset age on the pancreas size, morphology, and exocrine function.</p><p><strong>Methods: </strong>176 children with newly diagnosed T1D and 100 age- and sex-matched controls were enrolled in this retrospective study. Clinical metrics and pancreatic MRI parameters were collected and compared, and correlation analyses were performed to explore the relationships.</p><p><strong>Results: </strong>Pancreas volume, pancreas volume index (PVI), pancreas body and tail diameters, pancreas surface area, pancreas tail-to-spleen signal ratio, and pancreatic border irregularity score were lower, and pancreas surface area-to-volume ratio was higher in the T1D group than in the control group. T1D-DKA subgroup had a lower pancreas tail-to-spleen signal ratio and pancreatic border irregularity score than T1D-diabetic ketosis (T1D-DK) subgroup. Subgroup with an onset age under 10 years had a lower pancreas volume, pancreas head, body, and tail diameters, and pancreas surface area than subgroup with an onset age of 10 years or older. Several pancreatic MRI indices correlated with C-peptide levels in the T1D group, T1D-DK subgroup, and T1D-DKA subgroup but not in the T1D-alone subgroup. The integrated assessment of pancreatic size, morphology, and MR signal characteristics more effectively distinguishes the pancreas of T1D children from that of controls when compared to evaluating these factors individually.</p><p><strong>Conclusion: </strong>T1D affects the size, morphology and exocrine function of the pancreas in children, which is associated with DKA, islet cell function and onset age.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}